| Autor: |
Fares, Amneh A, Martinez, Diana, Musleh Ud Din, Saba, Wilkinson, Robert, Chavez, Julio C, Vargas Madueno, Fernando Manuel, Sandoval-Sus, Jose |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2329-2329, 1p |
| Abstrakt: |
Background:Despite recent advances in the treatment of B-cell non-Hodgkin lymphomas (NHL), most patients with relapsed/refractory (R/R) disease are at high risk of dying from their disease. Bispecific antibodies (BsAbs) are novel therapies with favorable response rates in R/R B-cell NHL even after cellular therapies. Mosunetuzumab, epcoritamab, glofitamab, and odronextamab are CD20 targeting BsAbs that have proven efficacy for R/R B-cell NHL. These treatments are generally well tolerated, but the infectious complications are not well described in the literature. Our study aims to quantify the relative incidence of infections associated with B-cell NHL targeted BsAbs. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
